JP2023552998A5 - - Google Patents

Info

Publication number
JP2023552998A5
JP2023552998A5 JP2023533999A JP2023533999A JP2023552998A5 JP 2023552998 A5 JP2023552998 A5 JP 2023552998A5 JP 2023533999 A JP2023533999 A JP 2023533999A JP 2023533999 A JP2023533999 A JP 2023533999A JP 2023552998 A5 JP2023552998 A5 JP 2023552998A5
Authority
JP
Japan
Prior art keywords
gene
cells
immune cells
edited
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552998A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/072715 external-priority patent/WO2022120370A2/en
Publication of JP2023552998A publication Critical patent/JP2023552998A/ja
Publication of JP2023552998A5 publication Critical patent/JP2023552998A5/ja
Pending legal-status Critical Current

Links

JP2023533999A 2020-12-03 2021-12-02 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 Pending JP2023552998A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063121206P 2020-12-03 2020-12-03
US63/121,206 2020-12-03
US202163201159P 2021-04-15 2021-04-15
US63/201,159 2021-04-15
US202163236167P 2021-08-23 2021-08-23
US63/236,167 2021-08-23
US202163264234P 2021-11-17 2021-11-17
US202163264223P 2021-11-17 2021-11-17
US63/264,223 2021-11-17
US63/264,234 2021-11-17
PCT/US2021/072715 WO2022120370A2 (en) 2020-12-03 2021-12-02 Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy

Publications (2)

Publication Number Publication Date
JP2023552998A JP2023552998A (ja) 2023-12-20
JP2023552998A5 true JP2023552998A5 (cg-RX-API-DMAC10.html) 2024-12-10

Family

ID=81854915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533999A Pending JP2023552998A (ja) 2020-12-03 2021-12-02 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用

Country Status (6)

Country Link
US (1) US20240335536A1 (cg-RX-API-DMAC10.html)
EP (1) EP4255453A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023552998A (cg-RX-API-DMAC10.html)
AU (1) AU2021392809A1 (cg-RX-API-DMAC10.html)
CA (1) CA3200367A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022120370A2 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
MX2022015586A (es) * 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
CN120152722A (zh) * 2022-06-24 2025-06-13 奥尔吉尼西丝公司 具有修饰的铰链和跨膜结构域的嵌合抗原受体及其用途
CN117384853B (zh) * 2022-07-11 2025-12-19 士泽生物医药(苏州)有限公司 一种表达pvr的通用型细胞及其制备方法
CN117384852B (zh) * 2022-07-11 2026-01-16 士泽生物医药(苏州)有限公司 一种表达lgals9的通用型细胞及其制备方法
JP2025525864A (ja) * 2022-08-03 2025-08-07 ンカルタ・インコーポレイテッド ナチュラルキラー細胞の機能を増強するための標的遺伝子の遺伝子編集
CN120092090A (zh) * 2022-11-07 2025-06-03 上海先博生物科技有限公司 工程化嵌合抗原受体免疫细胞及其应用
JP2025538424A (ja) * 2022-11-16 2025-11-28 ンカルタ・インコーポレイテッド 併用療法の投与レジメン
CN115948341B (zh) * 2022-11-28 2025-05-16 上海恩凯细胞技术有限公司 敲低nkg2a基因的car-免疫细胞及其用途
WO2024211554A1 (en) * 2023-04-07 2024-10-10 Nkarta, Inc. Methods for treatment of autoimmune diseases
EP4788796A1 (en) * 2023-10-05 2026-08-12 ONK Therapeutics Limited Optimised il-15 constructs
WO2025146467A1 (en) 2024-01-04 2025-07-10 Onk Therapeutics Limited Targeted il-15 construct delivery
WO2026041793A1 (en) * 2024-08-23 2026-02-26 BioNTech SE Chimeric proteins comprising non-human protein domains for enhancing antigenicity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
WO2016142532A1 (en) * 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
US10648020B2 (en) * 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
JP7033453B2 (ja) * 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法
MX2018010484A (es) * 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
WO2018126074A1 (en) * 2016-12-30 2018-07-05 Celularity, Inc. Genetically modified natural killer cells
CN110168078B (zh) * 2017-01-06 2024-05-14 免疫生物公司 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
JP2021502077A (ja) * 2017-11-06 2021-01-28 エディタス・メディシン,インコーポレイテッド 免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素
WO2019178422A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
SG11202010763VA (en) * 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
AU2019386140B2 (en) * 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
KR20210116526A (ko) * 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
BR112021016046A2 (pt) * 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
CN114174325A (zh) * 2019-06-04 2022-03-11 恩卡尔塔公司 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
JP2023503652A (ja) * 2019-11-27 2023-01-31 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 腫瘍微小環境における免疫抑制に打ち勝つための操作されたt細胞及び腫瘍浸潤リンパ球
MX2022015586A (es) * 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
US20260000761A1 (en) * 2022-01-19 2026-01-01 Nkarta, Inc. Engineered immune cells with enhanced potency and uses of same in immunotherapy

Similar Documents

Publication Publication Date Title
US11001621B1 (en) Trifunctional T cell-antigen coupler and methods and uses thereof
US20240075143A1 (en) Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof
JP6285553B2 (ja) 抗cd30キメラ抗原受容体およびその使用
US10561686B2 (en) Modified cell expansion and uses thereof
US11566223B2 (en) Chimeric antigen receptor cell preparation and uses thereof
US11235004B2 (en) Lymphocyte cell lines and uses thereof
US20230210905A1 (en) T cell-antigen coupler with various construct optimizations
EP3980450A1 (en) Combinations of engineered natural killer cells and engineered t cells for immunotherapy
US11198737B2 (en) T cell-antigen coupler with Y177 mutation and methods of uses thereof
WO2017059796A1 (en) Activation and expansion of t cells
KR20230066007A (ko) 신규한 보조자극 도메인을 포함하는 키메라 항원 수용체 및 이의 용도
JP2025513626A (ja) Ciita遺伝子がノックアウトされた操作された免疫細胞及びその用途
CN117187185A (zh) 一种工程化免疫细胞及其用途
CN115873801A (zh) 工程化免疫细胞及其用途
WO2023035947A1 (zh) 工程化免疫细胞及其用途
WO2023083003A1 (zh) 工程化免疫细胞及其用途
WO2023071811A1 (zh) 工程化免疫细胞及其用途
CN111607596A (zh) 修饰的pd-1及其在细胞治疗中的用途
HK1234091A1 (en) Trifunctional t cell-antigen coupler and methods and uses thereof